US artificial intelligence drug discovery firm Chai Discovery has secured $70 million in Series A funding, drawing backing ...

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Chiesi’s idebenone within ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...

The Parkinson’s disease (PD) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK and Japan ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Ireland-headquartered Jazz Pharmaceuticals’ ...

Swiss generics and biosimilar major Sandoz today presented its financial results for the first half of 2025. and reiterated ...

Shares of US clinical-stage company Eledon Pharmaceuticals shot up 9.9% to close at $3.44 yesterday, after it announced ...

Merck & Co (NYSE: MRK) was the biggest spender in pharma M&A during July. The US pharma giant boldly splashed out around $10 ...

US pharma major Eli Lilly’s shares plunged more than 14% to $630.61 after it announced what was seen by the market ...

USA-based biotech DoveTree Medicines has signed a far-reaching partnership with Chinese drug discovery company XtalPi (HKEX: 2228), in a deal worth up to $5.99 billion.

China-based Everest Medicines (HKEX: 1952) has secured full regulatory approval for Nefecon (budesonide) in Taiwan, marking the last of its Asian territories to grant the go-ahead for the ...

The initial small tariff on pharmaceutical imports will be increased to 150% within 18 months and eventually to 250%, according to President Trump’s comments in a CNBC interview.